ADAM10 targeting has also been explored in cancers, such as glioblastoma, Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, and breast cancer (reviewed in [74,84]). The gene discussed is ADAM10; the disease is plasma cell myeloma.